159 related articles for article (PubMed ID: 38193494)
1. The role of ASXL1 mutations and ASXL1 CircRNAs in cancer.
Jafarbeik-Iravani N; Kolahdozan S; Esmaeili R
Biomarkers; 2024 Feb; 29(1):1-6. PubMed ID: 38193494
[TBL] [Abstract][Full Text] [Related]
2. Identification of epithelial-mesenchymal transition-related circRNA-miRNA-mRNA ceRNA regulatory network in breast cancer.
Sang M; Wu M; Meng L; Zheng Y; Gu L; Liu F; Sang M
Pathol Res Pract; 2020 Sep; 216(9):153088. PubMed ID: 32825956
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC; Agosto-Peña J
Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
[TBL] [Abstract][Full Text] [Related]
4. Functional and cancer genomics of ASXL family members.
Katoh M
Br J Cancer; 2013 Jul; 109(2):299-306. PubMed ID: 23736028
[TBL] [Abstract][Full Text] [Related]
5. The role of ASXL1 in hematopoiesis and myeloid malignancies.
Asada S; Fujino T; Goyama S; Kitamura T
Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
[TBL] [Abstract][Full Text] [Related]
6. Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors.
Braun TP; Estabrook J; Schonrock Z; Curtiss BM; Darmusey L; Macaraeg J; Enright T; Coblentz C; Callahan R; Yashar W; Taherinasab A; Mohammed H; Coleman DJ; Druker BJ; Demir E; Lusardi TA; Maxson JE
Leukemia; 2023 Feb; 37(2):478-487. PubMed ID: 36526735
[TBL] [Abstract][Full Text] [Related]
7. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
Fujino T
Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
[TBL] [Abstract][Full Text] [Related]
9. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
Abdel-Wahab O; Gao J; Adli M; Dey A; Trimarchi T; Chung YR; Kuscu C; Hricik T; Ndiaye-Lobry D; Lafave LM; Koche R; Shih AH; Guryanova OA; Kim E; Li S; Pandey S; Shin JY; Telis L; Liu J; Bhatt PK; Monette S; Zhao X; Mason CE; Park CY; Bernstein BE; Aifantis I; Levine RL
J Exp Med; 2013 Nov; 210(12):2641-59. PubMed ID: 24218140
[TBL] [Abstract][Full Text] [Related]
10. Multiomics of Bohring-Opitz syndrome truncating ASXL1 mutations identify canonical and noncanonical Wnt signaling dysregulation.
Lin I; Wei A; Awamleh Z; Singh M; Ning A; Herrera A; ; Russell BE; Weksberg R; Arboleda VA
JCI Insight; 2023 May; 8(10):. PubMed ID: 37053013
[TBL] [Abstract][Full Text] [Related]
11. Functional roles of circular RNAs during epithelial-to-mesenchymal transition.
Shang BQ; Li ML; Quan HY; Hou PF; Li ZW; Chu SF; Zheng JN; Bai J
Mol Cancer; 2019 Sep; 18(1):138. PubMed ID: 31526370
[TBL] [Abstract][Full Text] [Related]
12. p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation.
Yang F; Hu A; Guo Y; Wang J; Li D; Wang X; Jin S; Yuan B; Cai S; Zhou Y; Li Q; Chen G; Gao H; Zheng L; Tong Q
Mol Cancer; 2021 Sep; 20(1):123. PubMed ID: 34579723
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
Wang L; Birch NW; Zhao Z; Nestler CM; Kazmer A; Shilati A; Blake A; Ozark PA; Rendleman EJ; Zha D; Ryan CA; Morgan MAJ; Shilatifard A
Nat Cancer; 2021 May; 2(5):515-526. PubMed ID: 35122023
[TBL] [Abstract][Full Text] [Related]
14. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
15. [Role of ASXL1 mutation in myeloid malignancies].
Sheng MY; Zhou Y; Xu MJ; Yang FC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
[TBL] [Abstract][Full Text] [Related]
16. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
[TBL] [Abstract][Full Text] [Related]
17. Translation and functional roles of circular RNAs in human cancer.
Lei M; Zheng G; Ning Q; Zheng J; Dong D
Mol Cancer; 2020 Feb; 19(1):30. PubMed ID: 32059672
[TBL] [Abstract][Full Text] [Related]
18. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T
J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185
[No Abstract] [Full Text] [Related]
19. EMT related circular RNA expression profiles identify circSCYL2 as a novel molecule in breast tumor metastasis.
Yuan C; Luo X; Zhan X; Zeng H; Duan S
Int J Mol Med; 2020 Jun; 45(6):1697-1710. PubMed ID: 32236616
[TBL] [Abstract][Full Text] [Related]
20. Review on circular RNAs and new insights into their roles in cancer.
Tang X; Ren H; Guo M; Qian J; Yang Y; Gu C
Comput Struct Biotechnol J; 2021; 19():910-928. PubMed ID: 33598105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
